SVB Leerink Weighs in on Jazz Pharmaceuticals plc’s FY2025 Earnings (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) – Equities research analysts at SVB Leerink upped their FY2025 earnings per share (EPS) estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Monday, January 23rd. SVB Leerink analyst M. Goodman now forecasts that the specialty pharmaceutical company will post earnings per share of $18.94 for the year, up from their previous estimate of $18.59. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $15.17 per share. SVB Leerink also issued estimates for Jazz Pharmaceuticals’ FY2026 earnings at $20.19 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.35 by $0.18. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive return on equity of 30.71%. The business had revenue of $940.65 million for the quarter, compared to analyst estimates of $939.88 million.

Several other research firms also recently weighed in on JAZZ. The Goldman Sachs Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and dropped their price target for the company from $192.00 to $190.00 in a research note on Thursday, December 8th. Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday, November 10th. Royal Bank of Canada raised their price target on shares of Jazz Pharmaceuticals from $206.00 to $207.00 and gave the stock an “outperform” rating in a research report on Thursday, November 10th. Finally, StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 21st. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $202.55.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $153.15 on Tuesday. The company has a market cap of $9.64 billion, a price-to-earnings ratio of -510.50, a PEG ratio of 0.91 and a beta of 0.74. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.16 and a quick ratio of 2.27. The stock’s fifty day moving average price is $154.72 and its 200 day moving average price is $149.93. Jazz Pharmaceuticals has a 1 year low of $125.36 and a 1 year high of $169.98.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 3,000 shares of the company’s stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $159.86, for a total value of $479,580.00. Following the completion of the transaction, the chief executive officer now owns 368,078 shares of the company’s stock, valued at approximately $58,840,949.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 372,028 shares of the company’s stock, valued at $55,804,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $159.86, for a total transaction of $479,580.00. Following the completion of the transaction, the chief executive officer now directly owns 368,078 shares in the company, valued at $58,840,949.08. The disclosure for this sale can be found here. Insiders have sold a total of 18,258 shares of company stock valued at $2,817,148 in the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System lifted its holdings in Jazz Pharmaceuticals by 1.2% in the 4th quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock valued at $2,692,000 after purchasing an additional 200 shares in the last quarter. National Bank of Canada FI grew its stake in Jazz Pharmaceuticals by 50.0% during the 4th quarter. National Bank of Canada FI now owns 2,691 shares of the specialty pharmaceutical company’s stock valued at $429,000 after acquiring an additional 897 shares in the last quarter. Park Avenue Securities LLC lifted its stake in Jazz Pharmaceuticals by 2.3% in the 4th quarter. Park Avenue Securities LLC now owns 3,100 shares of the specialty pharmaceutical company’s stock worth $494,000 after purchasing an additional 70 shares in the last quarter. Xponance Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 13.0% during the 4th quarter. Xponance Inc. now owns 8,333 shares of the specialty pharmaceutical company’s stock worth $1,328,000 after purchasing an additional 957 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Jazz Pharmaceuticals by 456.2% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 128,374 shares of the specialty pharmaceutical company’s stock valued at $20,451,000 after purchasing an additional 105,293 shares in the last quarter. Hedge funds and other institutional investors own 89.79% of the company’s stock.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.